Strengthening Partnerships: Dr. Hisham S. Aljadhey opened a workshop at the SFDA headquarters focused on enhancing collaboration between the SFDA and specialized medical associations, highlighting the importance of effective communication and cooperation.
Key Discussion Topics: The workshop covered vital areas such as developing educational programs on drug safety, disseminating information about medication risks, conducting research, and encouraging the reporting of drug side effects.
Ongoing Collaboration Efforts: The event underscored the SFDA’s commitment to building stronger relationships with medical associations, gathering expert input, and integrating healthcare professionals' perspectives to improve product safety and public health.
On September 10, 2024, Dr. Hisham S. Aljadhey, Chief Executive Officer of the Saudi Food and Drug Authority (SFDA), inaugurated a pivotal workshop at the SFDA headquarters in Riyadh. This significant event, attended by presidents and members of specialized medical associations, was designed to reinforce and expand collaborative efforts between the SFDA and the medical community.
In his opening address, Dr. Aljadhey underscored the critical importance of the workshop in strengthening the partnership between the SFDA and various medical associations. He highlighted the value of developing robust communication channels and fostering closer collaboration with healthcare practitioners. Dr. Aljadhey emphasized that such partnerships are essential for the effective implementation of the SFDA’s 'Fourth Strategy,' which is dedicated to enhancing product safety. This strategy aims to build trust among healthcare professionals and improve the dissemination of information related to health products.
The workshop provided a comprehensive overview of the pharmaceutical sector in Saudi Arabia, showcasing several successful collaborative initiatives between the SFDA and medical associations. Dr. Aljadhey and other speakers emphasized the need for ongoing dialogue and joint efforts to address shared challenges and achieve mutual goals.
Key topics of discussion included the development of educational programs focused on drug safety and effectiveness, the dissemination of critical information regarding medication risks, and the conduct of research studies to advance knowledge in the field. Additionally, participants explored ways to engage with scientific data published by the SFDA and encouraged the active reporting of drug side effects to enhance overall patient safety.
The workshop also aimed to gather valuable input from medical specialists, identify new areas for collaboration, and further integrate the perspectives of healthcare professionals into the SFDA’s regulatory framework. By fostering these connections and enhancing collaborative efforts, the SFDA seeks to improve the overall efficacy and safety of healthcare products in the Kingdom.
This event is part of the SFDA’s broader strategy to build and sustain meaningful relationships with medical associations, ensuring that the expertise of healthcare professionals is utilized effectively in regulatory processes. The workshop reflects the SFDA’s commitment to advancing public health and safety through enhanced cooperation and continuous improvement in regulatory practices.